Evidence map›Paper›PMID 42714406›Full record

ArticleAntimicrobial agents and chemotherapy2026

Comparative effectiveness of ceftolozane/tazobactam relative to ceftazidime/avibactam for the treatment of adult, hospitalized patients with pneumonia due to multidrug-resistant

Nicholas S Britt, Karim Khader, Tao He, Emily M Potter, Thomas P Lodise

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nicholas S BrittDepartment of Pharmacy Practice, University of Kansas School of Pharmacy, Lawrence, Kansas, USA.ORCID 0009-0004-7823-2570
Karim KhaderDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Tao HeDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Emily M PotterDwight D. Eisenhower Veterans Affairs Medical Center, Leavenworth, Kansas, USA.
Thomas P LodiseDepartment of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.ORCID 0000-0002-4730-0655

Funding

Merck & Co., Inc.
6 · The paper itself

Abstract

Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (C/A) are frequently used for the treatment of multidrug-resistant

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeCephalosporinsPneumonia, BacterialPseudomonas aeruginosaPseudomonas InfectionsTazobactamAgedDrug CombinationsDrug Resistance, Multiple, BacterialFemaleHumansMaleMiddle AgedRetrospective StudiesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeceftolozane, tazobactam drug combinationCephalosporinsDrug CombinationsTazobactamThird Generation Cephalosporinsantimicrobial stewardshipavibactambeta-lactamceftazidimeceftolozanemultidrug-resistancepneumoniaPseudomonas aeruginosatazobactamVeterans Health Administration

Identifiers

PMID42714406
PMCPMC13689478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.